Janux Therapeutics (JANX) Return on Capital Employed (2021 - 2026)
Janux Therapeutics' (JANX) quarterly Return on Capital Employed came in at 16.42% in Q1 2026, down 549.0% year-on-year from 3.66% in Q1 2025, and down 2.92% on a QoQ basis from 15.96% in Q4 2025.
Janux Therapeutics (JANX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 6 years of Return on Capital Employed data on file, last reported at 16.42% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 549.0% year-over-year to 16.42% in Q1 2026; TTM through Mar 2026 was 16.42%, a 549.0% decrease from a year earlier, with the FY2025 full-year figure at 15.66%, down 161.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 16.42%, down from 15.96% in the prior quarter.
- Over the last five years, Return on Capital Employed for JANX reached as high as 9.72% in Q2 2024 and fell as low as 23.48% in Q2 2023.
- Historically, Return on Capital Employed has averaged 15.85% across 5 years, with a median of 15.16% in 2022.
- Across the five-year window, Return on Capital Employed slumped 1158 bps in 2022 and soared 1376 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 18.99% in 2022, then fell by 4 bps to 19.69% in 2023, then jumped by 42 bps to 11.48% in 2024, then sank by 39 bps to 15.96% in 2025, then slipped by 3 bps to 16.42% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 16.42% in Q1 2026, 15.96% in Q4 2025, and 14.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Janux Therapeutics | 985.11 Mn | 985.11 Mn | - | -16.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.42% |
| Dec 31, 2025 | -15.96% |
| Sep 30, 2025 | -14.42% |
| Jun 30, 2025 | -14.20% |
| Mar 31, 2025 | -10.94% |
| Dec 31, 2024 | -11.48% |
| Sep 30, 2024 | -12.72% |
| Jun 30, 2024 | -9.72% |
| Mar 31, 2024 | -13.90% |
| Dec 31, 2023 | -19.69% |
| Sep 30, 2023 | -21.48% |
| Jun 30, 2023 | -23.48% |
| Mar 31, 2023 | -21.56% |
| Dec 31, 2022 | -18.99% |
| Sep 30, 2022 | -17.11% |
| Jun 30, 2022 | -15.16% |
| Mar 31, 2022 | -12.22% |
| Dec 31, 2021 | -8.84% |
| Sep 30, 2021 | -5.53% |